Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic

Authors

Dianne Nicol, University of Tasmania, Australia
Lisa Eckstein, University of Tasmania, Australia
Michael Morrison, University of Oxford, UK.
Jacob S. Sherkow, University of Tasmania, Australia
Margaret Otlowski, University of Tasmania, Australia
Tess Whitton, University of Tasmania, Australia
Tania M. Bubela, Simon Fraser University, CanadaFollow
Kathryn P. Burdon, University of Tasmania, Australia
Don Chalmers, University of Tasmania, Australia
Sarah Chan, University of Edinburgh, UK.

Document Type

Response or Comment

Department

Office of the Provost

Abstract

Genome editing using clustered regularly interspersed short palindromic repeats (CRISPR) and CRISPR-associated proteins offers the potential to facilitate safe and effective treatment of genetic diseases refractory to other types of intervention. Here, we identify some of the major challenges for clinicians, regulators, and human research ethics committees in the clinical translation of CRISPR-mediated somatic cell therapy.

Comments

Pagination are not provided by the author/publisher. This work was published before Tania joined Aga Khan University.

Publication (Name of Journal)

Genome Medicine

DOI

10.1186/s13073-017-0475-4

Recommended Citation

Nicol, D., Eckstein, L., Morrison, M., Sherkow, J. S., Otlowski, M., Whitton, T., Bubela, T. M., Burdon, K. P., Chalmers, D., Chan, S. (2017). Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic. Genome Medicine, 9(1), 85.
Available at: https://ecommons.aku.edu/provost_office/741

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.